Low molecular weight proteins and enzymes in the urine of patients with bladder cancer – a pilot study

Zofia Marchewka¹, Beata Szymańska¹, Janusz Dembowski², Anna Długosz³, Agnieszka Piwowar³

¹Department of Toxicology, Laboratory of Environmental Nephrotoxicity Markers, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland
²Clinic of Urology and Urological Oncology, Faculty of Postgraduate Medical Training, Wrocław Medical University, Wrocław, Poland
³Department of Toxicology, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland

Introduction
A steady increase in cases of bladder cancer (BC) has been observed. Detection of unfavorable changes, especially in the early stages of disease, is crucial to medical procedure. There is still a need to search for new, non-invasive biomarkers of BC. The aim of this study was to estimate the levels of selected low molecular weight proteins (LMWP) and enzymes in the urine of patients at different BC stages and grades.

Material and methods
Urine samples from 46 patients with BC and 16 healthy controls were examined. We measured levels of LMWP such as: retinol-binding protein (RBP), β2-microglobulin (β2M), enzymes: N-acetyl-β-D-glucosaminidase (NAG), isoform (NAG-B) and also neutrophil gelatinase-associated lipocalin (NGAL).

Results
The levels of all examined parameters differed between patients and healthy subjects. Levels of NAG (p = 0.031), NAG-B (p = 0.023) and NGAL (p = 0.008), and total protein (p = 0.007) concentrations, were significantly higher in the BC patients than in the control group. Among the examined parameters, positive significant correlations were observed only between urinary NGAL concentration and tumor stages and grades. The highest percentages of changes in NGAL concentration were observed in tumor in situ (TIS) and G3grade patients.

Conclusions
Our study showed that urinary NGAL concentrations, as well as NAG and NAG-B activity, could be helpful noninvasive parameters for the diagnosis of BC. The most promising seems to be NGAL determination, but further study is needed on a larger group of participants in order to confirm this observation.

Key Words: bladder cancer • urine • NGAL • NAG • low molecular weight proteins

INTRODUCTION
Worldwide cancer statistics indicate that bladder cancer (BC) constitutes about 3% of all cancer cases. BC represents the most expensive type of cancer per patient lifetime, and generates very high cost-of-illness and health care (about 5 billion EUR per year in the European Union) [1, 2, 3]. Although bladder cancer incidence and mortality rates have been dropping slightly in recent years worldwide, this tendency has not been observed among Poles. The incidence of BC in Poland rises around 5% per annum, due to the detection of BC late, when the disease is already in a high stage of advancement [4, 5].

Bladder cancer demonstrates a close causative relationship with exposure to occupational and environmental factors. Moreover, chronic inflammation of the urinary bladder, e.g. induced by Schistosoma haematobium or genetic predisposition, is not without significance [6, 7]. The main symptoms, such as hematuria or an urgent need to urinate, which may be accompanied by dysfunction such as pain or micturition, may suggest pre-existing bacterial cystitis rather than a cancerous process [1, 6]. No specific symptoms appear at the early stages of bladder
cancer, hence it is necessary to search for new diagnosti
c methods or biomarkers (e.g. proteins, enzymes, cytokines, genes), which could enable the early detection of BC as well as improving the diagnostic utilization of the existing ones. Research is needed from which markers will emerge which could be useful in the diagnosis of BC, and from the patient’s point of view, it is important that these diagnosti
c methods are non-invasive [8–11].

Cystoscopy remains the gold standard for the diagnosi
s and monitoring of BC disease, whereas cytology urine sediment is the standard non-invasive test performed on urine [2, 6]. Although many markers are under investigation, no spectacular breakthrough has been achieved so far. The Food and Drug Admini

stration (FDA) currently approve several tests for the diagnosis and/or monitoring of bladder cancers: BTA stat and BTA TRAK, NMP 22 BladderChek, UroVysion and ImmunoCyt/UCyt+ is recommended for monitoring relapse. These tests are not performed routinely in Europe, but are available in some laborato-
s. However these tests still have low specificity when compared to urinary cytology [12, 13]. To date, the concept of a single marker as a base for clinical decision has not proven sufficient and has not been recommended [14]. A good solution to this problem seems to be the creation of a panel of the best non-invasive markers, with the highest sensitivi
ty and specificity.

Some low molecular weight proteins (LMWP) and some hydrolytic enzymes, such as β-(microglobulin (β-M) and retinol binding protein (RBP), as well as N-acetyl-β-D-glucosaminidase (NAG) and its isoform B (NAG-B) respectively, have a well-known presence in kidney diseases. These biomarkers are especially related to renal tubular damage in different renal disorders [15, 16], however data about their changes in bladder cancer are still insufficient. The neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2, has also recently been of increasing interest to scientists, especially regarding human cancer, and is considered to be one of the most promising next-generation biomarkers in clinical nephology, as well as other diseases and pathological conditions [17, 18]. Higher levels of NGAL and its complex with matrix metalloproteinases (MMP) were observed in breast cancer, gastric cancer and BC with metastasis to the lymph nodes and the prostate [19, 20, 21].

The aim of this study was to examine a panel of low molecular weight proteins and enzymes such as β-M and RBP, NAG and its isoform NAG-B and NGAL in the urine of patients with bladder cancer, and to attempt to establish their relationship to the stage and grade of BC.

**MATERIAL AND METHODS**

The biological material for this study was obtained from 46 bladder cancer patients (37 men, 9 women), aged from 36 to 87 years old (mean age 69). All participants were examined in the Department of Urology and Urological Oncology of Wroclaw Medical University. Bladder cancer patients had clinical diagnoses of bladder cancer confirmed by histopathology examinations, and no additional diseases of the urinary tract had been detected. The tumors were classified by grade and stage according to TNM Classifications of Malignant Tumours [22]. The histopathological characteristics of the examined patients were as follows: 21 of them were diagnosed as Ta staging, 13 as T1, 6 as T2, and 6 as TIS. According to BC grading, 16 of them were identified as G1, 21 as G2, and 9 as G3. The control group comprised 16 adults (11 men and 5 women) aged from 54 to 81 years old (mean age of 67). Controls were selected from participants with no history of cancer or other chronic inflammation, which was excluded by clinical exami

nation of the cytology of urine sediment and a urine strip test. The BC patients and subjects from the control group were of similar socioeconomic status and there were no significant differences between these groups. All participants were informed of the aim of the study and gave written consent to participate. The approval of the Local Bioethics Committee of Wroclaw Medical University was obtained (Nr-360/2016).

A morning sample of urine was collected from all participants, in polyethylene containers without pre-

servatives. Morphological elements were removed by centrifugation for 10 min at 1440 rpm. The remaining urine was stored at -80°C until the determination of low molecular weight proteins and enzyme levels took place. Urinary concentration of β-M and RBP, as well as NGAL, were measured immunoenzymatically with appropriate, specific methods (Demeditec Diagnostics GmbH, Geramny; Immundiagnostik, Germany; BioPorto Diagnostics, Denmark, respectively). The activity of NAG was measured spe-
trophotometrically using p-nitrophenyl-N-acetyl-

β-D-glucosaminide as substrate. Its thermostable isoform – NAG-B, was measured using the same sub-

strate but after previous sample incubation at 500C for 120 minutes [23]. All results were calculated per mg of creatinine in urine samples. Creatinine con-

centration was measured by the Jaffe method using reactions with picric acid in acid conditions, using the routine laboratory method [24]. Total protein concentration was also measured spectrophotometrically using Total Protein Kit Micro Pyrogallol Red Method (Sigma, USA).
Statistical analysis

Statistical analysis of the obtained results was carried out using Statistica PL version 12.0. Quantitative variables are provided as the mean ± standard deviation and median with minimum (min) and maximum (max) values. Data analysis was performed using Student’s t-test or ANOVA test after checking normal distribution of results by Kolmogorov-Smirnov and Lilliefors tests. The associations between continuous variables were analyzed by the Spearman for nonparametric data and Pearson for parametric data tests. In all of the performed analyses, a p-value less than 0.05 was considered as statistically significant.

RESULTS

Concentrations of total protein and low molecular weight proteins (β₂M, RBP), enzyme NAG and its isoform (NAG-B) activity, and concentration of NGAL, expressed as mean and standard deviations, as well as medians with min and max values are presented in Table 1, along with statistical analysis. In the patients with bladder cancer the levels of all examined parameters differed in comparison to the control group, but significantly higher mean activity of NAG and NAG-B, as well as concentration of NGAL and total proteins were observed only in patients. The greatest difference was revealed in NGAL concentrations, which were almost twice as high in bladder cancer patients than in the control group. The activities of NAG and its isoform were higher in BC patients, from 49.2 to 64.3%, respectively. Moreover, statistically significant positive correlations (r = 0.9486, p < 0.001) between NAG and NAG-B were detected in the urine of patients with different bladder cancer stages was demonstrated only for NGAL (R = 0.3606, p < 0.05).

Based on these significant differences of NGAL in subgroups of patients with different stages of bladder cancer we also examined whether bladder cancer grade can be connected with the level of this enzyme.

Table 1. Urinary levels of examined parameters in bladder cancer patients and control group. Results were expressed as mean and standard deviation as well as median with minimum and maximum values

| Parameter | Control group (n = 16) | Patients group (n = 46) | p value |
|-----------|------------------------|-------------------------|---------|
| Protein [mg/ml] | 0.152 ± 0.091 (0.057–0.385) | 0.465 ± 0.498 (0.010–1.901) | p = 0.0072 |
| β₂M [μg/mg creat.] | 0.246 ± 0.278 (0.043–0.911) | 0.136 ± 0.072 (0.040–0.420) | p >0.05 |
| RBP [μg/mg creat.] | 0.128 ± 0.089 (0.022–0.314) | 0.192 ± 0.180 (0.005–1.151) | p >0.05 |
| NAG [U/mg creat.] | 1.770 ± 1.635 (0.811–3.403) | 2.468 ± 1.694 (0.656–10.671) | p = 0.0315 |
| NAG-B [U/mg creat.] | 1.125 ± 0.605 (0.212–2.540) | 1.778 ±1.454 (0.244–8.809) | p = 0.0225 |
| NGAL [ng/mg creat.] | 25.587 ± 14.133 (7.433–50.730) | 47.735 ±45.110 (1.691–184.261) | p = 0.0080 |

β₂M – β₂-microglobulin; RBP – retinol-binding protein; NAG, NAG-B – N-acetyl-β-D-glucosaminidase and isoenzyme B of N-acetyl-β-D-glucosaminidase, respectively; NGAL – neutrophil gelatinase-associated lipocalin; p – statistically significant difference.
Interestingly, the average values of NGAL concentration raised in particular subgroups depended on the cancer grade (G1, G2, G3) and amounted to: 24.610 ng/mg cr., 49.735 ng/mg cr. and 70.928 ng/mg cr., respectively. The concentrations of NGAL in the grade G3 subgroup were significantly higher than those observed in patients with G2 and G1 (p = 0.0351 and p = 0.0295, respectively). Additionally, a significant positive correlation was observed between urinary concentration of NGAL and subgroups of patients with different bladder cancer grades (R = 0.3787, p < 0.05). In Figure 1 the percentage of changes of NGAL levels is presented, depending on the stage and grade of bladder cancer, and with respect to the control group. In TIS stage as well as G3 grade of bladder cancer patients, similar percentages of differences between NGAL concentrations in relation to the control group were observed (286.92 % and 296.70%, respectively).

Estimating the influence of smoking, age and gender on the levels of examined parameters in the urine of bladder cancer patients, a lack of statistically significant differences between men and women, smoking and non-smoking patients and older (>67 years old) and younger (<67 years old) patients was observed (data not shown).

DISCUSSION

Cancer pathogenesis and development is very complex process and is connected with many different agents – oxidative, immune, inflammatory, nutritional, environmental, and others [25–28]. The search for different, noninvasive parameters, which could reflect the carcinogenic process occurring within the bladder is still of great relevance. Up to now the best universally applicable method for the detection of bladder cancer has been cystoscopy with biopsy, but this is an invasive examination for patients [2]. In our study we used noninvasive biological material, such as morning urine samples, to estimate levels of selected LMWP, such as β2M and RBC, and enzymes, such as NAG and its isoenzyme NAG-B, as well as NGAL, in BC patients with different stages and grades, to estimate whether they are connected with BC development. Analysis of 38 publically available microarray datasets and the Human Protein Atlas tool showed that NGAL transcripts were significantly higher in the majority of solid tumors compared to relatively normal tissues for every dataset analyzed. Furthermore, concordance of NGAL at both mRNA and protein levels was observed for 6 cancer types, including bladder, colorectal, liver, lung, ovarian, and pancreatic. All metastatic tumors showed a decrease in NGAL expression when compared to matched primary lesions (analysis of mRNA and NGAL expression, an immunohistochemistry). According to these results, the authors stated that NGAL is a candidate marker for tumor growth in a fraction of solid tumors. Further investigations are required to elucidate the function of NGAL in tumor development and metastatic processes [29, 30]. We observed varying degrees of change in levels of all the examined parameters between patients with bladder cancer and the control group, as well as among patients with different bladder cancer stages and grades, but the most significant differences were observed for NGAL concentration and additionally for the activity of NAG and its isoenzyme – NAG-B. Although the levels of low molecule proteins (RBP and β2M) in the subgroup of patients we examined were slightly different, significantly higher levels of RBP were found in stage T2 in comparison to stage Ta and TIS. In patients with inva-

### Table 2. Mean urinary levels of examined biochemical parameters in subgroups of patients depending on the staging of bladder cancer and in the control group

| Parameters | B,M [μg/mg cr.] | RBP [μg/mg cr.] | NAG [mU/mg cr.] | NAG-B [mU/mg cr.] | NGAL [ng/mg cr.] |
|------------|----------------|----------------|-----------------|-------------------|-----------------|
| Stage of bladder cancer | | | | |
| Ta         | 0.101 ±0.036   | 0.092 ±0.089   | 2.420 ±1.114    | 1.689 ±1.077      | 30.468 ±28.270  |
| T1         | 0.116 ±0.037   | 0.174 ±0.083   | 2.578 ±0.917    | 1.936 ±0.902      | 35.584 ±27.919  |
| T2         | 0.107 ±0.041   | 0.261 ±0.019   | 3.402 ±2.102    | 2.259 ±1.268      | 53.960 ±13.456  |
| TIS        | 0.071 ±0.010   | 0.074 ±0.050   | 3.083 ±2.100    | 2.257 ±2.055      | 68.592 ±3.604   |
| Control group | 0.161 ±0.002 | 0.120 ±0.065   | 1.770 ±0.694    | 1.125 ±0.605      | 23.906 ±14.381  |

Statistical analysis

| Ta, T1, T2, TIS – appropriate cancer staging; β2M – β2-microglobulin; RBP – retinol-binding protein; NAG, NAG-B – N-acetyl-β-D-glucosaminidase and isoenzyme B of N-acetyl-β-D-glucosaminidase, respectively; NGAL – neutrophil gelatinase-associated lipocalin; p1 – cancer stage T1 vs. control group; p2 – cancer stage T2 vs. control group; p3 – cancer stage T1 vs. control group; p4 – cancer stage T2 vs. TIS; p5 – cancer stage T2 vs. TIS; p6 – cancer stage T1 vs. TIS | p1 = 0.001 p2 = 0.0155 p3 = 0.0581 p4 <0.001 p5 <0.001 p6 = 0.0652 | p1 = 0.0464 p2 = 0.0244 p3 = 0.0153 p4 <0.001 p5 <0.001 p6 = 0.0581 | p1 = 0.0024 p2 = 0.0017 p3 = 0.0224 p4 <0.001 p5 <0.001 p6 = 0.0581 | p1 = 0.0581 p2 = 0.0581 p3 = 0.0581 p4 <0.001 p5 <0.001 p6 = 0.0581 |
sive BC, Tyler et al. [31] showed a significantly lower serum level of RBP in comparison to healthy people. Some authors indicate the role of disturbances of vitamin D and RBP in the etiology not only of bladder but also other cancers [32]. NAG is especially well known as a marker of diabetic nephropathy and other renal diseases [33, 34]. NAG is present in free form in the lysosomes of many cells. The source of its increased activity in the urine of patients may be not only the damaged lysosomes of epithelial cells, but also phagocytic cells comprising NAG in their azurophilic granules, which could be involved in the ongoing local inflammatory process [35, 36]. In explaining the pathomechanism of increased urinary excretion of NAG, its isoenzyme – NAG-B, which is attached to the lysosomal membrane, is very helpful. Its increased level in urine is a result of the rupture of the membrane integrity of these organelles, and may suggest deeper destructive changes in the cells during the development of BC. In the present study, excretion of this isoenzyme remains highly correlated with the activity of NAG, indicating extensive cell damage in patients with urinary BC. Elevated levels of urinary NAG were previously confirmed by Youssef et al. [35] in rat bladder carcinogenesis. Różanski et al. [36], evaluating the usefulness of NAG in the diagnosis of bladder cancer in postmenopausal women, showed an increased expression at the mRNA level of NAG in the urine of the examined women. The connection and influence of the enzyme on cancer development is not fully understood. It is believed that increased production of NAG can lead to disruption of the mitotic cell cycle [36, 37]. Our research found significantly higher levels of NGAL in the urine of patients with BC in comparison to healthy subjects, as well as the most significant differences in the subgroups of patients with different stages and grades of bladder cancer. Additionally we revealed that urinary NGAL concentrations increased with tumor stages and grades. This suggests that NGAL increase may result from the induced expression of this lipocalcin by damaged epithelium cells. Induction of NGAL synthesis may also be caused by factors stimulating cancer development, e.g. polyomaviruses, hepatocyte growth factors (HGF) or nuclear transcription factor NF-kappa B (NF-κB) [38, 39, 40]. Moreover we found that the urinary concentrations of NGAL in patients with stage TIS of bladder cancer were significantly higher than its concentrations in the control group or in patients at stages Ta and T1. In this light, NGAL appears to be a promising biomarker, which in the future may facilitate the diagnosis of this tumor stage. Interestingly the highest NGAL concentration was observed not only in patients at TIS stage, but also at G3 grade.

Interestingly NGALR, a cell surface receptor for NGAL, was also identified and the co-expression of both NGAL and NGALR has been implicated in different cancers [17, 30]. Moreover, most studies concern changes of NGAL concentration in the serum of bladder cancer patients, while fewer studies refer to urine, so the changes revealed are interesting and promising. Increasing attention is paid to NGAL as a cancer biomarker, but differential expression patterns are indicated. Monier et al. [41] examined levels of metalloproteinases and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) in different urothelial carcinomas. The authors observed, by western blot densitometry, an imbalance in MMP-9/TIMP-1 and MMP-2/TIMP-2 pairs, and changes in NGAL concentration in an unselected cohort of transitional cell carcinoma patients. An imbalance in MMP-9/TIMP-1 and MMP-2/TIMP-2 correlated with histological progression and clinical events, and was more pronounced at latter stages of progression compared to normal urinary enzyme profiles, but such a clear relationship was not observed for NGAL. The authors concluded that the obtained results were not straightforward, as a decrease in active MMP-9 and lack of NGAL are also associated with disease progression, and confirmation is required from a larger and more homogenous cohort, although it can be confirmed already that the degradation process of the epithelial basement membrane provides clues for understanding underlying cancer mechanisms. It is indicated that NGAL complex, with metalloproteinase-9, may be responsible for a procarcinogenic effect, and on the other hand may protect from the proteolytic degradation of enzymes, thus enhancing its activity. MMP-9 is responsible...
for extracellular matrix destruction, which increases the risk of invasiveness of cancer and the risk of metastasis [19, 42, 43]. This is confirmed by Mohamed et al. [44], who showed that the concentration of these complexes in the urine of BC patients was elevated in patients with higher grades of cancer, and in those who have metastasizes to the lymph nodes and the prostate. The results we obtained also indicate the potential use of NGAL as an early diagnostic and prognostic marker of BC, and, importantly, when estimated in urine.

CONCLUSIONS

In our study, we paid attention to a new aspect, which has not previously been considered, the existence of interrelations between changes in urinary NGAL concentrations and NAG and NAG-B activity, and the stages and grades of BC. Urinary NGAL level seems promising due to its highest concentration in patients with TIS stage and G3 grade. Our findings indicate that it might have diagnostic value and may be used as prognostic marker after deeper research. It is, however, important to estimate the sensitivity and specificity of NGAL by performing further studies of a larger number of patients with different stages and grades of BC.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

This study was supported by Wroclaw Medical University statutory activity – STD150.16.013.

References

1. Krajewski W, Kołodziej A, Dembowski J, Zdrojowy R. Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer. Post Hig Med Dosw. 2014; 68: 291-300.

2. Kowalska M, Fukiewicz M, Kotowicz B, et al. Clinical utility of tumor markers and cytokines assessment in patients with bladder cancer. Diagn Lab. 2009; 45: 149-154.

3. Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic Burden of Bladder Cancer Across the European Union. Eur Urol. 2016; 69: 438-447.

4. Key Statistics for Bladder Cancer. https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html (access date 19.08.2017).

5. Tuchowska P, Worach-Kardas H, Marcinkowski JT. The most frequent malignant tumors in Poland – the main risk factors and opportunities to optimize preventive measures. Probl Hig Epidemiol. 2013; 94: 166-171.

6. Kirilk IJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder cancer risk from occupational and environmental exposures. Urol Oncol. 2012; 30: 199-211.

7. Volanis D, Kadiyska T, Galanis A, Delakas D, Logothetis S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett. 2010; 193: 131-137.

8. Catto JWF. Old and New Urinary Markers: Which One is the PSA for Bladder Cancer? Eur Urol Suppl. 2008; 7: 422-425.

9. Sharma S. Tumor markers in clinical practice: General principles and guidelines. Indian J Med Paediatr Oncol. 2009; 30: 1-8.

10. Soukup V, Kalousová M, Capoun O, et al. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma. Urol Int. 2015; 95: 56-64.

11. Rybottycza Z, Dlugosz A. Diagnostic significance of protein NMP22 in bladder cancer. Pol Merkuriusz Lek. 2015; 38: 309-314.

12. Descotes F, Kara N, Decaussin-Petrucci M, et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017; 117: 583-587.

13. Bangma CH, Loeb S, Busstra M, et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol. 2013; 64: 41-47.

14. Soukup V, Kalousová M, Capoun O, et al. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma. Urol Int. 2015; 95: 56-64.

15. Szymanek-Pasternaka A, Marchewka Z, Szymańska B, et al. Assessment of the usefulness of β2-microglobulin and retinol binding protein for the purpose of testing kidney function in HIV-positive patients. HIV AIDS Rev. 2013; 14: 40-45.

16. Skálová S. The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica (Hradec Kralove). 2005; 48: 75-80.

17. Monisha J, Padmavathi G, Bordoloi D, Roy NK, Kunnumakkara A. Neutrophil Gelatinase – Associated Lipocalin (NGAL): A promising Biomarker for Cancer Diagnosis and A Potential Target for Cancer Therapeutics. J Cell Sci Molecul Biol. 2014; 1: 1-6.

18. Marchewka Z, Tack A, Piwowar A. [KIM-1 and NGAL as potential biomarkers for the diagnosis and cancer progression]. Post Hig Med Dosw (online). 2016; 70: 329-336.

19. Provatopoulou X, Gounaris A, Kalogeris E, et al. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex. MMP-9/NGAL in breast cancer disease. BMC Cancer. 2009; 9: 390.

20. Wang HJ, He XJ, Ma YY, et al. Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat Rec (Hoboken). 2010; 293: 1855-1863.

21. Urquidi V, Rosser CJ, Goodison S. Multiplex urinary tests for bladder cancer diagnosis. Eur Med J Urol. 2013; 1: 70-73.
22. Hoboken NJ. Urological tumour. In: TNM Classification of Malignant Tumors. Sobin LH, Gospodarowicz M, Wittekind C. (eds). 7th edition. Wiley-Blackwell, London; 2009; pp. 262-265.

23. Jung K, Mattenheimer H, Burchardt U. (eds.) Urinary enzymes. In: Clinical and Experimental Medicine. Springer-Verlag, Berlin; 1992; pp. 99-145.

24. Chromý V, Rozkosná K, Sedlák P. Determination of serum creatinine by Jaffe method and how to calibrate to eliminate matrix interference problems. Clin Chem Lab Med. 2008; 46: 1127-1133.

25. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49: 1603-1616.

26. Pandya PH, Murray ME, Pollok KE, Renbarger JL. The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. J Immunol Res. 2016; 2016: 4273943.

27. Du W, Fang JY1. Nutrients Impact the Pathogenesis and Development of Colorectal Cancer. Gastrointest Tumors. 2016; 2: 203-207.

28. Szymańska B, Sawicka E, Guzik A, Zdrojowy R, Długosz A. The diagnostic value of nuclear matrix proteins in bladder cancer in the aspect of environmental risk from carcinogens. Biomed Res Int. 2017; 2017: 9643139.

29. Knowles M, Hurst C. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015; 15: 25-41.

30. Candido S, Maestro R, Polesel J, et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014; 5: 1576-1594.

31. Tyler HA, Notley RG, Schweitzer FA, Dickerson JW. Vitamin A status and bladder cancer. Eur J Surg Oncol. 1986; 12: 35-41.

32. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer. 2012; 107: 1589-1594.

33. Piwower A, Knapiń-Kordecka M, Fusi I, Warwas M. Urinary activities of cathepsin B, N-acetyl-β-D-glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus. Med Sci Monit. 2006; 12: CR210-CR214.

34. Du W, Shen T, Li H, et al. Urinary NGAL for the diagnosis of the renal injury from multiple myeloma. Cancer Biomark. 2017; 18: 41-46.

35. Youssef EM, Wanibuchi H, Mori S, Salim El, Hayashi S, Fukushima S. Elevation of urinary enzyme levels in rat bladder carcinogenesis. Carcinogenesis. 1999; 20: 1247-1252.

36. Różański W, Lipiński M, Woźniak P, et al. Diagnostic value of β-N-acetyl-D-glucosaminidase and endoglin as molecular markers in postmenopausal women with urinary bladder neoplasms. Menopause Rev. 2011; 3: 197-201.

37. Krześlak A. Role of O-GlcNAc modification of cellular proteins in signal transduction. Post Bioch. 2007; 53: 389-399.

38. Di Carlo A. The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res. 2012; 12. http://dx.doi.org/10.7362/2240-2594.057.2012

39. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010; 4: 265-280.

40. Bostrom P, van Rhijn B, Fleschner N, et al. Staging and Staging Errors in Bladder Cancer. Eur Urol Suppl. 2010; 9: 2-9.

41. Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F, Zapiu P. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas. Eur Urol. 2002; 42: 356-363.

42. Bolignano D, Donato V, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene. Cancer Lett. 2010; 288: 10-16.

43. Ricci S, Bruzzone D, Di Carlo A. Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer. Oncol Lett. 2015; 10: 2527-2532.

44. Mohammed MA, Seleim MF, Abdalla MS, Sharada HM, Wahab AH. Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urology. 2013; 13: 5.